Dorothee E. Schliephake

Author

Kreussler (Germany)

Also Known As

D E Schliephake, D Schliephake, D. Schliephake, Dorothee E. Schliephake, Dorothee Schliephake

Publications

486

Citations

H-Index

Concepts

All Affiliations

Kreussler (Germany)Boehringer Ingelheim (Germany)University of Bonn

About

Dorothee E. Schliephake is an author at Kreussler (Germany) specializing in vascular surgery, thrombosis, and surgery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	172
2	Vascular Surgery	1	1	172
3	Anesthesiology	1	1	172
4	Surgery	1	1	172
5	Thrombosis	1	1	172

Dorothee E. Schliephake

Publications

482

Citations

H-Index

Page 1

	Year	Citations
Efficacy and Safety of Great Saphenous Vein Sclerotherapy Using Standardised Polidocanol Foam (ESAF): A Randomised Controlled Multicentre Clinical Trial Eberhard Rabe, Joachim Otto, Dorothee E. Schliephake, European Journal of Vascular and Endovascular Surgery ThrombosisVenous DiseaseEndovascular TechniqueVascular SurgeryPolidocanol Foam	2007	172
Blimp‐1 overcomes the block in IgM secretion in lipopolysaccharide / anti‐μ F(ab′)<sub>2</sub>‐co‐stimulated B lymphocytes Dorothee E. Schliephake, Anneliese Schimpl European Journal of Immunology	1996	88
Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study) Eberhard Rabe, Dorothee E. Schliephake, Joachim Otto, Phlebology The Journal of Venous Disease	2010	78
The French Polidocanol Study on Long-Term Side Effects J J Guex, Dorothee E. Schliephake, Joachim Otto, Dermatologic Surgery	2010	40
Concept for a study design in patients with severe community-acquired pneumonia: A randomised controlled trial with a novel IGM-enriched immunoglobulin preparation – The CIGMA study Tobias Welte, R. Phillip Dellinger, Henning Ebelt, Respiratory Medicine	2015	36
Efficacy and safety of Aethoxysklerol<sup>®</sup> (polidocanol) 0.5%, 1% and 3% in comparison with placebo solution for the treatment of varicose veins of the lower extremities in Chinese patients (ESA-China Study) Jun Zhang, Zaiping Jing, Dorothee E. Schliephake, Phlebology The Journal of Venous Disease	2011	29
A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects Willem Hettema, Christopher Wynne, Benjamin Lang, Expert Opinion on Investigational Drugs	2017	29
Phase 3 Trial of BI 695502 Plus Chemotherapy Versus Bevacizumab Reference Product Plus Chemotherapy in Patients With Advanced Nonsquamous NSCLC Edward S. Kim, Sigrid Balser, Klaus Röhr, JTO Clinical and Research Reports	2021	10

Page 1